Prurigo nodularis
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
relevance score : -100.0%
ReferencesPrurigo nodularis jẹ ipo awọ‑ara ti o ti pẹ ti o ni ijuwe nipasẹ ọpọlọpọ awọn àkúnya àti nodules, tí a máa rí nígbà gbogbo lórí àwọn apá àtàwọn ẹsẹ. Àwọn àkúnya wọ̀nyí lè yàtọ̀ ní àwọ̀ láti ara‑toned sí pink, tí ó sì lè wulẹ̀ yún gan‑an. Wọ́n lè ní ipa lórí ènìyàn tí ó wà ní ọjọ‑ori kankan, tí ó sì máa ń bá a lọ̀pọ̀ ìpò àwọ̀‑ara míì tí ń fa nyún oníbàjẹ́, bíi atopic dermatitis. Àwọn aṣàyàn ìtọ́jú ní í ṣe pẹ̀lú àwọn oogun anti‑itch tó lagbara, àwọn oogun tó ní ipa lórí eto ajẹsara, àti àwọn oogun tó ń fojúṣọ́ eto aifọkanbalẹ. Ṣíṣàkóso Prurigo nodularis sábà máa ń jẹ́ ìtọ́jú tó ń gba àkókò pípẹ.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Itọju maa n jẹ lilo awọn ipara tabi awọn abẹrẹ ti steroid lori agbegbe ti o kan. Ni awọn ọran ti o nira tabi alagidi, awọn itọju bii phototherapy (ailera ina) tabi awọn oogun ti o dinku eto ajẹsara le nilo. Thalidomide ati lenalidomide jẹ awọn aṣayan fun awọn ọran ti o nira, ṣugbọn wọn le ni awọn ipa ẹgbẹ to ṣe pataki. Awọn itọju titun (opioid receptor antagonists, neurokinin-1 receptor antagonists) ti fihan ileri ninu itọju prurigo nodularis, pẹlu awọn ipa ẹgbẹ diẹ ju thalidomide tabi lenalidomide lọ.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo jẹ ipo awọ ara ti a ṣe apejuwe nipasẹ irẹwẹsi pipẹ (ti o gun ju ọsẹ 6 lọ), awọn ọgbẹ awọ ti o ni ibatan, ati itan‑kikan nigbagbogbo. O kan neuroinflammation ati fibrosis ninu awọ ara.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis jẹ́ àìlera awọ̀ ara tí ó ti pẹ́ tí a mọ̀ sí àwọn nodulu ń yún. A kò mọ̀ pátápátá ohun tí ó ń fa rẹ̀, ṣùgbọ́n ó dà bíi pé àìlera ajẹsára àti àwọn ìṣòro ara ń kópa nínú ìyípadà ìṣàn. Lónìí, kò sí ìtọ́jú kankan tí US FDA ti fọwọ́ sí fún Prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Itọju - Oògùn OTC
Fifọ́ àgbègbè ọ̀gbẹ́ pẹ̀lú ọṣẹ kò ràn lọ́́wọ́ rárá, ó sì lè mú kí ó bọ́ sí i. Àwọn ikunra sitẹriọdu OTC lè ràn lọ́́wọ́ láti yọkúrò nínú aami aisan, ṣùgbọ́n wọ́n sábà máa nílò lílo fún ọ̀sẹ̀ púpọ̀ kí a tó rí àìlera. Tí o bá ń tẹ̀síwájú láti mu antihistamine, ó tún lè ràn wá lọ́wọ́ láti dín àìlera kù.
#OTC steroid ointment
#OTC antihistamine
○ Itọju
#Intralesional triamcinolone injection